8-K: cbdMD Secures $1.25 Million in Funding Through Convertible Promissory Notes

cbdMD, Inc. has entered into a securities purchase agreement with institutional investors, securing $1.25 million in gross proceeds through the issuance of convertible promissory notes.

Summary

• cbdMD, Inc. has secured $1.25 million in funding through a securities purchase agreement with five institutional investors.
• The company issued Senior Secured Original Issue Discount Convertible Promissory Notes with an aggregate principal amount of $1,541,666.
• The notes bear an interest rate of 8% per annum and mature on July 30, 2025.
• The notes are convertible into common stock at an initial conversion price of $0.684 per share, subject to adjustments and a $0.30 floor price.
• The company intends to use the proceeds for working capital and general corporate purposes.
• The notes are secured by a first priority security interest.
• The company is required to file a proxy statement within 30 days and hold a special shareholder meeting within 90 days to approve the issuance of excess shares.

Sentiment

Score: 5

Explanation: The document indicates a necessary but potentially costly funding round. While the company secures capital, the terms of the convertible notes, including the discount and high default interest rate, suggest a moderate level of risk and a less favorable outcome for the company.

Positives

• The company has successfully raised $1.25 million in funding.
• The convertible notes provide a potential future source of equity capital.
• The funds will be used for working capital and general corporate purposes, which may support growth.

Negatives

• The notes have a 20% original issue discount, reducing the net proceeds received by the company.
• The notes are secured by a first priority security interest, potentially limiting the company's flexibility.
• The conversion price is subject to adjustments that could result in dilution for existing shareholders.
• The interest rate increases to 22% upon an event of default, which could be costly.

Risks

• The company may face challenges in meeting the terms of the notes, including the interest payments and conversion requirements.
• The conversion of the notes could lead to significant dilution of existing shareholders' equity.
• The company's ability to prepay the notes is contingent on the effectiveness of a registration statement.
• Failure to obtain shareholder approval for the issuance of excess shares could impact the company's ability to convert the notes fully.

Future Outlook

The company intends to use the proceeds for working capital and general corporate purposes, and the convertible notes provide a potential future source of equity capital. The company is required to file a proxy statement within 30 days and hold a special shareholder meeting within 90 days to approve the issuance of excess shares.

Industry Context

This funding round is typical for companies seeking capital for growth and operations. The use of convertible notes is a common method for raising capital, particularly for companies that may not be able to access traditional debt financing.

Comparison to Industry Standards

• The 8% interest rate on the convertible notes is within the typical range for similar financings, but the 20% original issue discount is relatively high, indicating a higher cost of capital.
• The conversion price of $0.684 per share, with a $0.30 floor, is a common structure for convertible notes, providing investors with potential upside while protecting against significant downside.
• The requirement for shareholder approval for the issuance of excess shares is a standard provision to protect existing shareholders from excessive dilution.
• The 22% default interest rate is a high penalty, reflecting the risk associated with the investment.

Stakeholder Impact

• Shareholders may experience dilution if the notes are converted into common stock.
• Employees may benefit from the company's improved financial position.
• Creditors may be impacted by the first priority security interest granted to the investors.

Next Steps

• The company will file a proxy statement within 30 days.
• The company will hold a special shareholder meeting within 90 days to approve the issuance of excess shares.
• The company will file a registration statement to register the conversion shares within 10 trading days.
• The company will cause the registration statement to be effective within 60 days.

Key Dates

Keywords

convertible notes, funding, securities purchase agreement, institutional investors, working capital, common stock, conversion price, shareholder approval, secured debt, promissory note